Evidence map›Paper›PMID 31526067›Full record

ArticleLeukemia & lymphoma2020

Levocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia.

Jessica L Sea, Etan Orgel, Ting Chen, Rebecca L Paszkiewicz, Abigail S Krall, Matthew J Oberley, Linsey Stiles, Steven D Mittelman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jessica L SeaDivision of Pediatric Endocrinology, UCLA Children's Discovery and Innovation Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-3812-9032
Etan OrgelDivision of Hematology, Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Ting ChenDivision of Pediatric Endocrinology, UCLA Children's Discovery and Innovation Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Rebecca L PaszkiewiczDivision of Pediatric Endocrinology, UCLA Children's Discovery and Innovation Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Abigail S KrallDepartment of Biological Chemistry and the Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Matthew J OberleyDepartment of Pediatrics, University of Southern California, Los Angeles, CA, USA.
Linsey StilesDivision of Endocrinology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Steven D MittelmanDivision of Pediatric Endocrinology, UCLA Children's Discovery and Innovation Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-2867-1298
University of California, Los Angeles · USUniversity of Southern California · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Adipocytes are Important Players in the Acute Lymphoblastic Leukemia MicroenvironmentR01CA201444 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MITTELMAN, STEVEN DAVID · 2016 to 2020
$1.9M
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA201444
6 · The paper itself

Abstract

Asparaginase (ASNase) is an integral part of pediatric induction chemotherapy that has also been shown to improve adult survival rates; however, pegylated (PEG)-ASNase induces severe hepatotoxicity in this population. Recent case reports describe the incorporation of levocarnitine (LC) supplementation into PEG-ASNase-containing induction regimens to prevent or treat hepatotoxicity. Because LC facilitates the metabolism of free fatty acids (FFA), a primary fuel source for ALL cells, LC could potentially interfere with ALL chemotherapy efficacy. To test this, we employed

Indexed as

CarnitinePrecursor Cell Lymphoblastic Leukemia-LymphomaAcute DiseaseAnimalsAntineoplastic Combined Chemotherapy ProtocolsAsparaginaseHumansInduction ChemotherapyMiceAsparaginaseCarnitineAcute lymphoblastic leukemia (ALL)hepatotoxicitylevocarnitine (L-carnitine)PEG-asparaginase

Identifiers

PMID31526067
PMCPMC7305023
OpenAlexW2974237362

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.